Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2019-10-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out the dose of enzalutamide that can be safely
given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
Researchers also want to find out the side effects of these drugs when given together. This
study will help in finding out the effect on tumor of the combination of enzalutamide,
gemcitabine and nab-paclitaxel. In the first part of the study, different doses of
enzalutamide will be tested. In the second part of the study, all patients will be started at
the same dose of enzalutamide.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute